HC Wainwright reaffirmed their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP – Free Report) in a research report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $12.00 target price on the stock.
Indaptus Therapeutics Price Performance
NASDAQ INDP opened at $1.43 on Wednesday. Indaptus Therapeutics has a one year low of $1.03 and a one year high of $3.25. The business has a 50 day simple moving average of $1.45 and a 200 day simple moving average of $1.99. The stock has a market capitalization of $12.21 million, a P/E ratio of -0.80 and a beta of 1.46.
Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.07. Equities analysts expect that Indaptus Therapeutics will post -1.72 earnings per share for the current year.
Institutional Inflows and Outflows
Indaptus Therapeutics Company Profile
Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
Read More
- Five stocks we like better than Indaptus Therapeutics
- How to Use the MarketBeat Stock Screener
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Best Stocks Under $10.00
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.